Erytech Pharma : Refocus stratégique sur les tumeurs solides
>Abandon du développement dans les cancers du sang - Erytech annonce ce matin un refocus stratégique sur les tumeurs solides et donc l’abandon du développement dans les tumeurs liquides. La répercussion directe est le retrait de la demande d’autorisation de mise sur le marché (AMM) en Europe pour GRASPA (eryaspase) dans l’indication LAL (Leucémie aigue lymphoblastique). Rappelons qu’initialement, Erytech s’était développé dans les tumeurs liquides. En effet, sa techno...Erytech Pharma is a pharmaceutical company based in France. Co. is primarily engaged in developing cancer therapies that work by starving tumors. Co.'s first product (ERY-ASP), which is in phase III development, provides a therapeutic solution to frail patients with acute leukemia. Co.'s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Co. maintains a production unit located in Lyons with "Pharmaceutical Establishment" status. Co. has also signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.